- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03342625
High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study (BRIFU)
High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study (Breast Resection By HIFU)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Incidence of breast cancer increases with the lifetime of the population, and represents an important socio-economic issue. Diagnosis and treatment are major public health issues. High Instensity Focused Ultrasound (HIFU) is a minimally invasive technique which decreases the risk of post-treatment complications and allows shorter hospitalization times. This technology is also remarkable for the absence of limitation related to the dose delivered, which makes it possible to repeat if necessary and the absence of ionizing radiation both for the treatment itself and for its guidance (MRI).
The main objective is to evaluate the efficacy of HIFU for the treatment of breast tumors, based on histological criteria.
Indication :
Histologically invasive ductal carcinoma, T0, with unifocal or plurifocal lesion, with or without associated microcalcifications, measuring 15 mm maximum on ultrasound and clinical N0.
Course of the study :
- Signature of consent,
- Clinical and radiological assessment at Baseline,
- Realization of the HIFU procedure under local anesthesia and sedation (J0),
- Total or partial mastectomy depending on the lesion (between D2 and D8),
- Consultation with surgeon (J30),
Number of patients :
15 patients will be included in this pilot study. If no success is observed, the study will be stopped and the technique considered inefficient. If there are one or more successes, an Independant Data Monitoring Committee (IDMC) will meet to propose an additional trial if necessary with the data from this trial.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean PALUSSIERE, MD
- Phone Number: +33 5 56 33 37 50
- Email: j.palussiere@bordeaux.unicancer.fr
Study Locations
-
-
-
Bordeaux, France, 33076
- Recruiting
- Institut Bergonie
-
Contact:
- Jean PALUSSIERE, MD
- Phone Number: +33 5 56 33 37 50
- Email: j.palussiere@bordeaux.unicancer.fr
-
Contact:
- Christine TUNON DE LARA, MD
- Phone Number: +33 5 56 33 33 35
- Email: c.tunondelara@bordeaux.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria :
- Histologically proven infiltrating ductal carcinoma with the analysis of hormone receptors, tumor grade, Her-2 expression.
- T0 lesion, unifocal or plurifocal, with or without micro-calcifications associated, measuring 15 mm maximum major axis on ultrasound.
- Clinical N0.
- Bra cup size greater than or equal to B.
- Markable and identifiable lesion in MRI.
- Indication of partial or total mastectomy in case of multifocal lesions or extensive calcification associated with axillary surgery.
- Breast assessment performed by a referent radiologist: Mammography, ultrasound, clinical examination.
- No contraindication to MRI.
Exclusion Criteria :
- Infiltrating lobular carcinoma and Pure ductal carcinoma in situ.
- Bilateral lesion.
- Non-detectable MRI lesions, within 10 mm of the skin, greater than 15 mm on ultrasound.
- Unifocal palpable tumor.
- Cup size bra equal to A.
- Cutaneous lesion on the breast to be treated by HIFU.
- Impossibility of ventral decubitus immobility, extended arm, during 1 hour.
- Pregnant or postpartum patient.
- Patient participating in another interventional clinical trial within 30 days of enrollment and during the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Intensity Focused Ultrasound
High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI
|
High Intensity Focused Ultrasound guided by MRI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of HIFU for the treatment of breast tumors, based on histological criteria
Time Frame: Day 30
|
|
Day 30
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Feasibility of non-invasive pre-surgical identification of the tumor area to be resected (palpation by the surgeon of the focused ultrasound ablation zone)
Time Frame: Day 2, 8
|
Day 2, 8
|
Immediate complications of focused ultrasound
Time Frame: Day 30
|
Day 30
|
Pain (visual analogue scale) experienced by patients during the sedation procedure, until surgery.
Time Frame: Day 0, 2
|
Day 0, 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Jean PALUSSIERE, MD, Institut Bergonie
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IB 2015-01
- ID-RCB number : 2017-A01490-53 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
Clinical Trials on High Instensity Focused Ultrasound
-
Philips HealthcareCompletedSecondary Malignant Neoplasm of BoneFrance
-
Marc Dall'Era, MDNational Cancer Institute (NCI)RecruitingLocalized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8United States
-
Shufang ChangRecruitingCervical Intraepithelial NeoplasiaChina
-
Hospices Civils de LyonWithdrawnPlacenta AccretaFrance
-
Centre Antoine LacassagneWithdrawn
-
University of North Carolina, Chapel HillFocused Ultrasound FoundationRecruitingPartial Seizures With Secondary GeneralizationUnited States
-
Chinese University of Hong KongTerminated
-
Imperial College LondonSonaCare MedicalUnknownCervical Cancer | Rectal Cancer | Rectal Neoplasms | Pelvic Cancer | Endometrial CancerUnited Kingdom
-
Jewish General HospitalUnknown
-
University Women's Hospital TübingenTheraclionCompletedBreast FibroadenomaGermany